Two key takeaway's for me from Mason's video: 1) What a shame...

Two key takeaway's for me from Mason's video:

1) What a shame the EMD AML trial was discontinued with a patient response rate so incredibly high when you combine the patients from both Sheba trials. Who knows how many more lives could have been extended/saved if clinicians actually recommended patients be screened before treatment.

I do hope this data is picked up on by Otsuka/Astex and given the compelling preclinical data on combining Bisantrene with Decitabine in solid tumours, then this segment of the patient population may eventually have an approved drug combination with compelling efficacy.

2) How necessary is it for RACE to develop a companion diagnostic given the number of cancer indications FTO may be a relevant target if Bisantrene is dosed correctly and potential 'universal' utility as a cardioprotective drug?

Thanks @Mason14 for taking the time to generously share your knowledge and contributions such as yours make HC a worthwhile site to visit as it was originally intended!